Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.

abstract：:Effective treatment of glioblastoma (GBM) remains a formidable challenge. Survival rates remain poor despite decades of clinical trials of conventional and novel, biologically targeted therapeutics. There is considerable evidence that most of these therapeutics do not reach their targets in the brain when administered...

journal_title：Neuro-oncology

authors： Vogelbaum MA,Aghi MK

更新日期：2015-03-01 00:00:00

abstract：:Brain metastasis, which occurs in 20% to 40% of all cancer patients, is an important cause of neoplastic morbidity and mortality. Successful invasion into the brain by tumor cells must include attachment to microvessel endothelial cells, penetration through the blood-brain barrier, and, of relevance, a response to bra...

journal_title：Neuro-oncology

authors： Denkins Y,Reiland J,Roy M,Sinnappah-Kang ND,Galjour J,Murry BP,Blust J,Aucoin R,Marchetti D

更新日期：2004-04-01 00:00:00

abstract：:Background Nuclear factor IA (NFIA), a transcription factor and essential regulator in embryonic glial development, is highly expressed in human glioblastoma (GBM) compared with normal brain, but its contribution to GBM and cancer pathogenesis is unknown. Here we demonstrate a novel role for NFIA in promoting growth a...

journal_title：Neuro-oncology

authors： Lee JS,Xiao J,Patel P,Schade J,Wang J,Deneen B,Erdreich-Epstein A,Song HR

更新日期：2014-01-01 00:00:00

abstract：:Epidermal growth factor receptor (EGFR) gene amplification and activating mutations are common findings in glioblastomas. EGFR is at the top of a downstream signaling cascade that regulates important characteristics of glioblastoma cells, including cellular proliferation, migration, and survival. Targeting EGFR has th...

journal_title：Neuro-oncology

authors： Roth P,Weller M

更新日期：2014-10-01 00:00:00

abstract：BACKGROUND:We report a phase I study to examine the pharmacokinetics, safety, and recommended dosage of weekly intravenous bolus 5-fluorouracil (5-FU) in children and young adults with recurrent ependymoma. METHODS:Patients 22 years of age or less with recurrent ependymoma were treated with bolus dosage 5-FU weekly fo...

journal_title：Neuro-oncology

authors： Wright KD,Daryani VM,Turner DC,Onar-Thomas A,Boulos N,Orr BA,Gilbertson RJ,Stewart CF,Gajjar A

更新日期：2015-12-01 00:00:00

abstract：:Death receptor targeting has emerged as one of the promising novel approaches of cancer therapy. The activation of one such prototypic death receptor, CD95 (Fas/APO-1), has remained controversial because CD95 agonistic molecules have exhibited either too strong toxicity or too little activity. The natural CD95 ligand ...

journal_title：Neuro-oncology

authors： Eisele G,Roth P,Hasenbach K,Aulwurm S,Wolpert F,Tabatabai G,Wick W,Weller M

更新日期：2011-02-01 00:00:00

abstract：BACKGROUND:No more than half of patients with neurofibromatosis type 1 (NF1)-associated optic pathway gliomas (OPGs) develop vision loss. Prospectively identifying those who will require therapy remains challenging, because no reliable factors have yet been identified that predict future vision loss. To determine wheth...

journal_title：Neuro-oncology

authors： de Blank PM,Berman JI,Liu GT,Roberts TP,Fisher MJ

更新日期：2013-08-01 00:00:00

abstract：BACKGROUND:Twenty-five germline variants are associated with adult diffuse glioma, and some of these variants have been shown to be associated with particular subtypes of glioma. We hypothesized that additional germline variants could be identified if a genome-wide association study (GWAS) were performed by molecular s...

journal_title：Neuro-oncology

authors： Eckel-Passow JE,Drucker KL,Kollmeyer TM,Kosel ML,Decker PA,Molinaro AM,Rice T,Praska CE,Clark L,Caron A,Abyzov A,Batzler A,Song JS,Pekmezci M,Hansen HM,McCoy LS,Bracci PM,Wiemels J,Wiencke JK,Francis S,Burns TC,

更新日期：2020-11-26 00:00:00

abstract：BACKGROUND:To examine the efficacy of valproic acid (VPA) given either with or without levetiracetam (LEV) on seizure control and on survival in patients with glioblastoma multiforme (GBM) treated with chemoradiation. METHODS:A retrospective analysis was performed on 291 patients with GBM. The efficacies of VPA and LE...

journal_title：Neuro-oncology

authors： Kerkhof M,Dielemans JC,van Breemen MS,Zwinkels H,Walchenbach R,Taphoorn MJ,Vecht CJ

更新日期：2013-07-01 00:00:00

abstract：:Intradural spinal tumors are rare tumors of the central nervous system. Due to the eloquence of the spinal cord and its tracts, the compact architecture of the cord and nerves, and the infiltrative nature of some of these tumors, surgical resection is difficult to achieve without causing neurological deficits. Likewis...

journal_title：Neuro-oncology

authors： Abd-El-Barr MM,Huang KT,Moses ZB,Iorgulescu JB,Chi JH

更新日期：2018-05-18 00:00:00

abstract：:Multiphoton excitation fluorescent microscopy is a laser-based technology that allows subcellular resolution of native tissues in situ. We have recently applied this technology to the structural and photochemical imaging of cultured glioma cells and experimental gliomas ex vivo. We demonstrated that high microanatomic...

journal_title：Neuro-oncology

authors： Kantelhardt SR,Leppert J,Krajewski J,Petkus N,Reusche E,Tronnier VM,Hüttmann G,Giese A

更新日期：2007-04-01 00:00:00

abstract：:The vasculature of 24 primary CNS B-cell lymphomas that were not related to acquired immunodeficiency syndrome was systematically studied by electron microscopy. Seven low-grade astrocytic tumors were included for comparison. Classical electron microscopy features of apoptosis were found in lymphoma cells of 21 of 22 ...

journal_title：Neuro-oncology

authors： Molnár PP,O'Neill BP,Scheithauer BW,Groothuis DR

更新日期：1999-04-01 00:00:00

abstract：BACKGROUND:Promoter methylation of O(6)-methylguanine-DNA methyltransferase (MGMT) is an important predictive biomarker in glioblastoma. The T variant of the MGMT promoter-enhancer single nucleotide polymorphism (SNP; rs16906252) has been associated with the presence of MGMT promoter methylation in other cancers. We ex...

journal_title：Neuro-oncology

authors： Rapkins RW,Wang F,Nguyen HN,Cloughesy TF,Lai A,Ha W,Nowak AK,Hitchins MP,McDonald KL

更新日期：2015-12-01 00:00:00

abstract：:Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor (VEGF) that has efficacy in recurrent malignant gliomas, particularly in combination with irinotecan. However, responses are rarely durable. Continuation of bevacizumab in combination with another chemotherapeutic agent may demon...

journal_title：Neuro-oncology

authors： Quant EC,Norden AD,Drappatz J,Muzikansky A,Doherty L,Lafrankie D,Ciampa A,Kesari S,Wen PY

更新日期：2009-10-01 00:00:00

abstract：BACKGROUND:The influence of survivin isoforms on outcome in glioblastoma is poorly understood. We analyzed the dominant anti-apoptotic transcript variants of survivin using expression data and modeled them in vivo to determine their impact on glioma formation and progression. METHODS:Using data from low- and high-grad...

journal_title：Neuro-oncology

authors： Doucette T,Latha K,Yang Y,Fuller GN,Rao A,Rao G

更新日期：2014-09-01 00:00:00

abstract：Background:CNS tumors, including medulloblastoma and pediatric glioblastoma (pGBM) account for the majority of solid pediatric malignancies. There remains an unmet need to identify novel treatment approaches in poor prognosis and relapsed pediatric brain tumors, where therapeutic options are limited. Small-molecule B-c...

journal_title：Neuro-oncology

authors： Levesley J,Steele L,Brüning-Richardson A,Davison A,Zhou J,Ding C,Lawler S,Short SC

更新日期：2018-01-22 00:00:00

abstract：BACKGROUND:The transcription factor homeobox C9 (HOXC9) plays a crucial role in developmental regulatory systems, where it determines the specific positional identities of cells along the anteroposterior axis. The expression of HOXC9 has been found to be dysregulated in some cancers such as lung cancer, breast cancer, ...

journal_title：Neuro-oncology

authors： Xuan F,Huang M,Liu W,Ding H,Yang L,Cui H

更新日期：2016-06-01 00:00:00

abstract：BACKGROUND:Available evidence on diet and glioma risk comes mainly from studies with retrospective collection of dietary data. To minimize possible differential dietary recall between those with and without glioma, we present findings from 3 large prospective studies. METHODS:Participants included 692 176 from the UK ...

journal_title：Neuro-oncology

authors： Kuan AS,Green J,Kitahara CM,De González AB,Key T,K Reeves G,Floud S,Balkwill A,Bradbury K,Liao LM,Freedman ND,Beral V,Sweetland S,Million Women Study, the NIH-AARP study, and the PLCO study.

更新日期：2019-07-11 00:00:00

abstract：:The effects of combining histone deacetylase (HDAC) inhibitors and proteasome inhibitors were evaluated in both established glioblastoma multiforme (GBM) cell lines and short-term cultures derived from the Mayo Clinic xenograft GBM panel. Coexposure of LBH589 and bortezomib at minimally toxic doses of either drug alon...

journal_title：Neuro-oncology

authors： Yu C,Friday BB,Yang L,Atadja P,Wigle D,Sarkaria J,Adjei AA

更新日期：2008-06-01 00:00:00

abstract：:Histone deacetylase inhibitors that increase histone acetylation on transformed cells are being investigated as unique anticancer drugs. The aim of this investigation was to evaluate an antiproliferative activity of the histone deacetylase inhibitors sodium butyrate (NaBT) and trichostatin A on 5 glioma cell lines, T9...

journal_title：Neuro-oncology

authors： Kamitani H,Taniura S,Watanabe K,Sakamoto M,Watanabe T,Eling T

更新日期：2002-04-01 00:00:00

abstract：BACKGROUND:Whole-brain radiotherapy (WBRT) in patients with brain metastases (BM) is associated with neurocognitive decline. Given its crucial role in learning and memory, efforts to mitigate this toxicity have mostly focused on sparing radiation to the hippocampus. We hypothesized that BM are not evenly distributed ac...

journal_title：Neuro-oncology

authors： Yanagihara TK,McFaline-Figueroa JR,Giacalone NJ,Lee AW,Soni V,Hwang ME,Hsieh KT,Saraf A,Wu CC,Yang D,Wen PY,Ashamalla H,Aizer AA,Wang TJC,Huang RY

更新日期：2019-05-06 00:00:00

abstract：:Glioblastoma multiforme, a highly aggressive tumor of the central nervous system, has a dismal prognosis that is due in part to its resistance to radio- and chemotherapy. The protein kinase C (PKC) family of serine threonine kinases has been implicated in the formation and proliferation of glioblastoma multiforme. Mem...

journal_title：Neuro-oncology

authors： Azoitei N,Kleger A,Schoo N,Thal DR,Brunner C,Pusapati GV,Filatova A,Genze F,Möller P,Acker T,Kuefer R,Van Lint J,Baust H,Adler G,Seufferlein T

更新日期：2011-07-01 00:00:00

abstract：:Survival alone is no longer an adequate outcome for persons with brain tumors; the quality of the survivorship experience should be viewed with equal importance. Symptom management is a significant component of quality survivorship care. Regardless of their histology, brain tumors and therapies used to treat them prod...

journal_title：Neuro-oncology

authors： Amidei C

更新日期：2018-11-09 00:00:00

abstract：BACKGROUND:RTOG 0625/ACRIN 6677 is a multicenter, randomized, phase II trial of bevacizumab with irinotecan or temozolomide in recurrent glioblastoma (GBM). This study investigated whether early posttreatment progression on FLAIR or postcontrast MRI assessed by central reading predicts overall survival (OS). METHODS:O...

journal_title：Neuro-oncology

authors： Boxerman JL,Zhang Z,Safriel Y,Larvie M,Snyder BS,Jain R,Chi TL,Sorensen AG,Gilbert MR,Barboriak DP

更新日期：2013-07-01 00:00:00

abstract：:Identification of the epidermal growth factor receptor variant III (EGFRvIII) mutation in glioblastoma has become increasingly relevant in the optimization of therapy. Traditionally, determination of tumor EGFRvIII-expression has relied on tissue-based diagnostics. Here, we assess the accuracy of magnetic resonance pe...

journal_title：Neuro-oncology

authors： Tykocinski ES,Grant RA,Kapoor GS,Krejza J,Bohman LE,Gocke TA,Chawla S,Halpern CH,Lopinto J,Melhem ER,O'Rourke DM

更新日期：2012-05-01 00:00:00

abstract：:Tumor treating fields (TTFields) are low-intensity electric fields alternating at an intermediate frequency (200kHz), which have been demonstrated to block cell division and interfere with organelle assembly. This novel treatment modality has shown promise in a variety of tumor types. It has been evaluated in randomiz...

journal_title：Neuro-oncology

authors： Hottinger AF,Pacheco P,Stupp R

更新日期：2016-10-01 00:00:00

abstract：Background:Copy number alterations form prognostic molecular subtypes of glioblastoma with clear differences in median overall survival. In this study, we leverage molecular data from several glioblastoma cohorts to define the distribution of copy number subtypes across random cohorts as well as cohorts with selection ...

journal_title：Neuro-oncology

authors： Cimino PJ,McFerrin L,Wirsching HG,Arora S,Bolouri H,Rabadan R,Weller M,Holland EC

更新日期：2018-09-03 00:00:00

abstract：BACKGROUND:Adult pilocytic astrocytomas (PAs) are rare and have an aggressive clinical course compared with pediatric patients. Constitutive Ras/RAF/MAPK signaling appears to be an important oncogenic event in sporadic PA. We evaluated clinical data and molecular profiles of adult PAs at our institution. METHODS:We id...

journal_title：Neuro-oncology

authors： Theeler BJ,Ellezam B,Sadighi ZS,Mehta V,Tran MD,Adesina AM,Bruner JM,Puduvalli VK

更新日期：2014-06-01 00:00:00

abstract：:People with neurofibromatosis 1 (NF1) have multiple benign neurofibromas and a 10% lifetime risk of developing malignant peripheral nerve sheath tumors (MPNSTs). Most MPNSTs develop from benign plexiform neurofibromas, so the burden of benign tumors may be a risk factor for developing MPNST. We studied 13 NF1 patients...

journal_title：Neuro-oncology

authors： Mautner VF,Asuagbor FA,Dombi E,Fünsterer C,Kluwe L,Wenzel R,Widemann BC,Friedman JM

更新日期：2008-08-01 00:00:00

abstract：:Functional diffusion mapping (fDM) has shown promise as a sensitive imaging biomarker for predicting survival in initial studies consisting of a small number of patients, mixed tumor grades, and before routine use of anti-angiogenic therapy. The current study tested whether fDM performed before and after radiochemothe...

journal_title：Neuro-oncology

authors： Ellingson BM,Cloughesy TF,Zaw T,Lai A,Nghiemphu PL,Harris R,Lalezari S,Wagle N,Naeini KM,Carrillo J,Liau LM,Pope WB

更新日期：2012-03-01 00:00:00